- CME/CE Activities
- Disease-Modifying Antirheumatic Drugs for Children with JIA
This CME/CE activity is provided by PRIME Education, Inc. (PRIME®) and is accredited for a multi-disciplinary audience of health care practitioners. This activity is supported by contract number HHSA290201200021I from the Agency for Healthcare Research and Quality. User data collected through this activity will reside on PRIME's educational portal for use by AHRQ.
Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis
- Program Overview
- Faculty Biographies
- Accreditation Statements
- Post-Test & Evaluation
Credit for this CME/CE activity has expired.
You can still access the program, but will not receive a certificate.
Juvenile idiopathic arthritis (JIA) is the most common rheumatologic childhood disease, affecting 7 to 400 out of 100,000 children. The debilitating physical and mental health burden of this chronic disease on affected children, combined with the stress placed on their families, underlies the need for comparative effectiveness research to determine the most beneficial and safe treatment interventions.
In 2011, the Agency for Healthcare Research and Quality (AHRQ) published a comparative effectiveness review on treatments for JIA, including synthetic and biologic DMARDs. The review systematically examines the scientific studies on available outcome measures for JIA. The synthesis of this information clarifies the available evidence and can guide clinicians and families in making appropriate treatment decisions. The findings and potential clinical applications of the AHRQ review are presented in this educational monograph.
At the conclusion of this activity, the participant should be able to:
- Compare the effectiveness of conventional treatments versus newer synthetic or biologic disease-modifying anti-rheumatic drugs (DMARDs) for the following outcomes: symptoms, laboratory measures of inflammation, radiographic progression, and health status
- Describe the comparative effectiveness of various DMARDs on key clinical, laboratory, and radiographic outcome measures
- Summarize the rates and types of adverse events in comparisons between various DMARDs and between conventional treatments and DMARDs
- Apply the review findings to making effective, patient-centered treatment and management decisions
This CME activity is designed to meet the educational needs of this cme activity is designed to meet the educational needs of physicians, pharmacists, nurses, and case managers.
Method of Participation
To receive a certificate for this activity, you should:
- Complete the learner assessment pretest
- View the entire activity online
- Complete an online evaluation & post-test
- Print your certificate online
The estimated time to complete this activity, including review of the materials, is 1.0 hour.
Term of Approval
March 01, 2012 through September 30, 2013. Original release date: March 01, 2012.
Acknowledgement of Support
There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME®) and funded under contract HHSA290201200021I from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).
Faculty Biographies and Disclosures
Robert McMahan, PharmD, MBA, MATS
Vice President, Clinical Pharmacy Operations
Virginia Beach, VA
Brandon Bellows, PharmD
Health Economics and Outcomes Research Fellow
Pharmacotherapy Outcomes Research Center
University of Utah College of Pharmacy
Salt Lake City, UT
Laurence Greene, PhD
Director of Scientific Education and Outcomes
PRIME Education, Inc.
Lisa Balfe, MPH
PRIME Education, Inc (PRIME)
Frank L Urbano, MD, FACP
Medical Director, Care Management
Albert Einstein Medical Center
Assistant Professor of Medicine
Cooper Medical School of
Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
National Clinical Nursing Director
Department of Neurology
Multiple Sclerosis Center of Excellence, East Veterans Affairs Medical Center
Trinity Nursing Program School of Professional Studies, Trinity Washington University
Clinical Preceptor and Instructor
Advanced Practice Programs, The Catholic University of America School of Nursing
Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP
Adjunct Faculty & Preceptor
Albany College of Pharmacy
Kathleen A Jarvis, MS, RN, CCM
Fort Lauderdale, FL
Michael N Baxley, MD, MS, MPH
Chief of Quality Medical Initiative
MCCI Medical Group
President and Founder Physician
Managed Care Consulting Service Company
This program is no longer accredited.
|Faculty Name ||Advisory Board||Consultant||Grants / Research||Salary / Contractual||Supported Promotional Education||Stock / Shareholder||Other Financial Support|
|Robert McMahan, PharmD, MBA, MATS
|Brandon Bellows, PharmD
|Laurence Greene, PhD
|Lisa Balfe, MPH
|Frank L Urbano, MD, FACP
|Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
|Donna M Chiefari, BSc (Pharm), PharmD, RPh, FASHP
|Kathleen A Jarvis, MS, RN, CCM
|Michael N Baxley, MD, MS, MPH
|Chris R Prostko, PhD|
Scientific Program Director
|Lynn Goldenberg, RN, BSN|
Director of Accreditation & Compliance
PRIME Education Inc (PRIME®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
PRIME® willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.
Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.
Content validation methods are consistently utilized by PRIME® to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME® complete disclosures which are related to their role in the educational activity.
PRIME®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.
1. Access the Activity:
Adobe Acrobat Reader or equivalent is required to view this program.
Open the PDF Activity in New Tab
Post-Test & Evaluation
Credit for this program has expired.
If you already completed this program and need to reprint your certificate(s), login here.
Clinician & Consumer Summaries on JIA
Download these free summaries for your reference and/or patient handouts. You may also order bulk copies free of charge from the AHRQ Publication Clearinghouse below.